Clinical Trial

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

Study acronym: CONFIRMATION
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
Protocol Amendment History 3 changes
notable Trial sites expanded: 15 -> 104 locations 2026-07-24
notable Primary completion pushed: 2026-07 -> 2027-11 2026-07-24
minor Completion pushed: 2026-08 -> 2027-11 2026-07-24
Trial Details
NCT Number NCT06024746
Lead Sponsor Colorado Prevention Center
Collaborators: Saint Luke's Mid America Heart Institute, Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Conditions Heart Failure
Enrollment 1,500 participants
Start Date 2024-07-09
Primary Completion 2027-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-23